| abstract |
Described herein are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, twin dimers and mutual prodrugs are also described. TRPV1 agonist compound formulations may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a plaster or the like. Methods for treating medical conditions using the described compounds, compositions or prodrugs are also provided. |